Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 36235 results found since Jan 2013.
Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety, and quality of life
CONCLUSION: Combining ICIs with chemotherapy enhanced OS and PFS as well as not worsening HRQoL. Among all ICIs, PDL1 inhibitors showed better effectiveness. Future studies should focus on real world settings and more clinical trials using ICIs for not only ES-SCLC but also LS-SCLC.PMID:35575164 | DOI:10.1080/03007995.2022.2078101
Source: Current Medical Research and Opinion - May 16, 2022 Category: Research Authors: Rasika Korde Rajwanth Veluswamy Gisoo Barnes Source Type: research
Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview
CONCLUSION: Studies reporting TTD are increasing, most notably real-world studies. Given the increasing importance of TTD as an efficacy endpoint, it becomes critical to measure and monitor it in various therapeutic settings such as NSCLC. This is the first study to review all TTD values of drugs used in first-line NSCLC.PMID:36932463 | DOI:10.1080/03007995.2023.2192610
Source: Current Medical Research and Opinion - March 18, 2023 Category: Research Authors: Ruggero Lasala Andrea Zovi Valentina Isgr ò Alessia Romagnoli Felice Musicco Fiorenzo Santoleri Source Type: research
Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers
Int J Med Sci. 2023 May 11;20(7):858-869. doi: 10.7150/ijms.82008. eCollection 2023.ABSTRACTBiliary tract cancers (BTCs) are a heterogenous group of malignancies arising from the epithelial cells of the biliary tree and the gallbladder. They are often locally advanced or already metastatic at the time of the diagnosis and therefore prognosis remains dismal. Unfortunately, the management of BTCs has been limited by resistance and consequent low response rate to cytotoxic systemic therapy. New therapeutic approaches are needed to improve the survival outcomes for these patients. Immunotherapy, one of the newest therapeutic o...
Source: International Journal of Medical Sciences - June 16, 2023 Category: Biomedical Science Authors: Simone Conci Giovanni Catalano Diletta Roman Camilla Zecchetto Eleonora Lucin Mario De Bellis Marzia Tripepi Alfredo Guglielmi Michele Milella Andrea Ruzzenente Source Type: research
